Cellectis (NASDAQ:CLLS) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Cellectis (NASDAQ:CLLSGet Rating) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “

Separately, StockNews.com downgraded Cellectis from a hold rating to a sell rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $18.88.

Shares of NASDAQ:CLLS opened at $2.90 on Wednesday. The firm has a market capitalization of $131.92 million, a PE ratio of -1.15 and a beta of 2.24. Cellectis has a 1 year low of $2.85 and a 1 year high of $16.86. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.57 and a quick ratio of 4.57. The firm’s 50-day moving average is $4.07 and its two-hundred day moving average is $6.56.

Cellectis (NASDAQ:CLLSGet Rating) last released its earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.50. The company had revenue of $13.66 million for the quarter, compared to analyst estimates of $12.30 million. Cellectis had a negative net margin of 170.26% and a negative return on equity of 41.88%. During the same period in the prior year, the business earned ($0.95) EPS. Analysts expect that Cellectis will post -2.37 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. OLD Mission Capital LLC purchased a new stake in Cellectis during the 3rd quarter worth about $253,000. Deutsche Bank AG purchased a new stake in Cellectis during the third quarter worth approximately $42,000. BlackRock Inc. boosted its holdings in Cellectis by 5.9% in the third quarter. BlackRock Inc. now owns 312,256 shares of the biotechnology company’s stock valued at $3,937,000 after purchasing an additional 17,387 shares in the last quarter. KBC Group NV increased its stake in Cellectis by 29.1% in the third quarter. KBC Group NV now owns 163,447 shares of the biotechnology company’s stock valued at $2,061,000 after purchasing an additional 36,862 shares during the last quarter. Finally, US Bancorp DE increased its stake in Cellectis by 94.0% in the third quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,130 shares during the last quarter. Hedge funds and other institutional investors own 40.55% of the company’s stock.

Cellectis Company Profile (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Featured Articles

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.